Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of SK-1403

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Serum PTH\>240 pg/mL at the screening~* Serum corrected Ca≧8.4 mg/dL at the screening~* Stable chronic kidney disease patients who undergo hemodialysis or hemodialysis filtration~Exclusion Criteria:~* Primary hyperparathyroidism~* Severe liver disease~* Severe Cardiac disease~* History or family history of long QT syndrome~* Malignant tumor~* Uncontrolled diabetes mellitus~* Uncontrolled hypertension~* History of severe drug allergy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SK-1403 (Type: EXPERIMENTAL): Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
- Placebo (Type: PLACEBO_COMPARATOR): Patients receive Placebo three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.

Based on this trial design, predict the completion outcome and termination type (if applicable).